We’re pleased to announce topline results from our Phase 2 study in a type of pulmonary hypertension (#PH). Learn more here: http://merck.us/3XA4pNf
Truly professional!
i-Pharm GxP
1w
Congratulations, impressive milestone!
Encouraging to see Merck share Phase 2 progress in pulmonary hypertension. Clear communication of topline results helps peers track therapeutic momentum and anticipate next steps in resilience and patient access. Looking forward to how these findings shape the Phase 3 design and broader dialogue in the cardiovascular space.
Michael N.
1w
Applied via company website, open to relocation
Thank you for sharing